肺外结核患者治疗过程中系列18F-氟脱氧葡萄糖正电子发射断层扫描(18F-FDG PET)扫描表现——一项前瞻性观察性研究
这项前瞻性观察性研究纳入来自6个国家8个中心的147例HIV阴性肺外结核成人患者,在治疗前、治疗2个月及抗结核治疗结束时各行一次18F-FDG PET/CT扫描。结果显示活动性病灶数目及SUVmax随时间逐步下降,但按WHO推荐方案治疗结束时仅53/147(36.0%)患者PET/CT阴性,94/147(63.9%)仍为阳性。作者认为现有18F-FDG PET/CT技术尚不能作为临床治疗反应、治愈或停药的生物标志物。
要点
- 147例HIV阴性肺外结核患者完成3次系列18F-FDG PET/CT扫描,活动性病灶数目及SUVmax随时间逐步下降。
- 按WHO推荐方案治疗结束时53/147(36.0%)患者PET/CT阴性,94/147(63.9%)仍为阳性,其中12例发展为耐多药结核。
- 作者认为现有18F-FDG PET/CT技术尚不能临床用作治疗反应、治愈或停药决策的生物标志物。
核心结论
- 作者认为现有18F-FDG PET/CT影像技术尚不能临床用作肺外结核治疗反应、治愈或停药时机的生物标志物。
- 作者认为PET/CT仍是结核研究工具,需使用靶向高密度表面表位、基因靶点或代谢通路的新的结核分枝杆菌特异性放射性药物进一步开发PET/CT。
研究设计与样本
- 前瞻性观察性研究,纳入来自6个国家8个中心的HIV阴性肺外结核成人患者。
- 患者接受3次18F-FDG PET/CT扫描:入组2周内、结核治疗2个月时及抗结核治疗结束时。
- 扫描按EANM指南进行,静脉注射2.5-5.0 MBq/kg的18F-FDG后60±10分钟行18F-FDG PET/CT。
主要发现
- 147例肺外结核患者共接受3次系列扫描,活动性部位数目及这些部位的摄取水平(SUVmax)随时间逐步下降。
- 按WHO推荐方案治疗结束时,53/147(36.0%)患者PET/CT扫描阴性,94/147(63.9%)患者仍为PET/CT阳性。
- PET/CT仍阳性的94例患者中12例发展为耐多药结核,1例死于脑结核瘤。
临床怎么用
- 作者认为现有18F-FDG PET/CT影像技术不能临床用作肺外结核治疗反应、治愈或停药决策的生物标志物。
- 作者认为PET/CT仍是结核研究工具,需使用新的结核分枝杆菌特异性放射性药物进一步开发PET/CT。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Initial studies of tuberculosis (TB) in macaques and humans using 18F-FDG positron emission tomography (PET) imaging as a research tool suggest its usefulness in localising disease sites and as a clinical biomarker. Sequential serial scans in patients with extrapulmonary TB (EPTB) could inform on the value of PET-CT for monitoring response to treatment and defining cure. PATIENTS AND METHODS: HIV-negative adults with EPTB from eight sites across six countries had three 18F-FDG PET/CT scans: (i) within 2 weeks of enrolment, (ii) at 2 months into TB treatment and (iii) at end of ATT treatment. Scanning was performed according to the EANM guidelines. 18F-FDG PET/CT scans were performed 60 ± 10 min after intravenous injection of 2.5-5.0 MBq/kg of 18F-FDG. FINDINGS: One hundred and forty-seven patients with EPTB underwent 3 sequential scans. A progressive reduction over time of both the number of active sites and the uptake level (SUVmax) at these sites was seen. At the end of WHO recommended treatment, 53/147 (36.0%) patients had negative PET/CT scans, and 94/147 (63.9%) patients remained PET/CT positive, of which 12 patients had developed MDR TB. One died of brain tuberculoma. INTERPRETATION: Current 18F-FDG PET/CT imaging technology cannot be used clinically as a biomarker of treatment response, cure or for decision-making on when to stop EPTB treatment. PET/CT remains a research tool for TB and further development of PET/CT is required using new Mycobacterium tuberculosis-specific radiopharmaceuticals targeting high-density surface epitopes, gene targets or metabolic pathways.
引用
- Bomanji J, Sharma R, Mittal BR, et al. Sequential 18F-fluorodeoxyglucose positron emission tomography (18F-FDG PET) scan findings in patients with extrapulmonary tuberculosis during the course of treatment-a prospective observational study. Eur J Nucl Med Mol Imaging. 2020. PMID: 32483653. doi:10.1007/s00259-020-04888-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。